• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life

tetano

tetano

Editor, Senior Moderator
J Antimicrob Chemother. 2011 Mar 15. [Epub ahead of print]
Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life.

Kumar A.

Section of Critical Care Medicine and Infectious Diseases, Health Sciences Centre and St Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada.
Abstract

The need for early antimicrobial therapy is well established for life-threatening bacterial and fungal infections including meningitis and sepsis/septic shock. However, a link between the outcome of serious viral infections and delays in antiviral therapy is not as well recognized. Recently, with the occurrence of the influenza A/H1N1 pandemic of 2009, a large body of data regarding this issue has become available. Studies analysing data from this pandemic have consistently shown that delays in initiation of antiviral therapy following symptom onset are significantly associated with disease severity and death. Optimal survival and minimal disease severity appear to result when antivirals are started as soon as possible after symptom onset.

PMID: 21406435 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/21406435
 
Re: Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life

Optimal survival and minimal disease severity appear to result when antivirals are started as soon as possible after symptom onset.
Click to expand...
It is generally accepted that individuals exhibiting H5N1 influenza symptoms have the best chance of survival if treated with oseltamivir within 48 hours of symptom onset.This was recognized as early as 2005 in an article on oseltamivir resistance in two H5N1 patients in Vietnam.

The efficacy of oseltamivir is unlikely to be optimal when treatment is instituted late in the course of illness, as has been the case in most patients with influenza A (H5N1) virus infection reported to date.
Click to expand...
http://www.nejm.org/doi/full/10.1056/NEJMoa054512#t=articleTop
 
You must log in or register to reply here.
Back
Top Bottom